Jennison Associates LLC boosted its position in Exact Sciences Corporation (NASDAQ:EXAS) by 599.3% during the second quarter, according to its most recent Form 13F filing with the SEC. The fund owned 144,245 shares of the medical research company’s stock after buying an additional 123,618 shares during the period. Jennison Associates LLC owned about 0.12% of Exact Sciences Corporation worth $5,102,000 as of its most recent SEC filing.

Several other large investors have also recently modified their holdings of EXAS. BlackRock Inc. boosted its stake in shares of Exact Sciences Corporation by 45,816.0% in the first quarter. BlackRock Inc. now owns 6,804,297 shares of the medical research company’s stock worth $160,718,000 after buying an additional 6,789,478 shares in the last quarter. JPMorgan Chase & Co. boosted its stake in shares of Exact Sciences Corporation by 98.1% in the first quarter. JPMorgan Chase & Co. now owns 4,985,657 shares of the medical research company’s stock worth $117,761,000 after buying an additional 2,468,376 shares in the last quarter. Point72 Asset Management L.P. boosted its stake in shares of Exact Sciences Corporation by 1,534.3% in the first quarter. Point72 Asset Management L.P. now owns 2,500,476 shares of the medical research company’s stock worth $59,061,000 after buying an additional 2,347,476 shares in the last quarter. OppenheimerFunds Inc. boosted its stake in shares of Exact Sciences Corporation by 66.8% in the first quarter. OppenheimerFunds Inc. now owns 2,502,398 shares of the medical research company’s stock worth $59,107,000 after buying an additional 1,002,398 shares in the last quarter. Finally, Perceptive Advisors LLC boosted its stake in shares of Exact Sciences Corporation by 305.0% in the first quarter. Perceptive Advisors LLC now owns 410,000 shares of the medical research company’s stock worth $9,684,000 after buying an additional 610,000 shares in the last quarter. Institutional investors own 85.22% of the company’s stock.

Exact Sciences Corporation (EXAS) opened at 41.18 on Tuesday. Exact Sciences Corporation has a one year low of $13.05 and a one year high of $42.18. The firm’s market capitalization is $4.90 billion. The stock’s 50 day moving average is $38.63 and its 200 day moving average is $30.31.

Exact Sciences Corporation (NASDAQ:EXAS) last released its earnings results on Tuesday, July 25th. The medical research company reported ($0.27) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.37) by $0.10. The firm had revenue of $57.65 million during the quarter, compared to analyst estimates of $47.73 million. Exact Sciences Corporation had a negative net margin of 83.08% and a negative return on equity of 36.36%. On average, equities research analysts predict that Exact Sciences Corporation will post ($1.18) earnings per share for the current fiscal year.

ILLEGAL ACTIVITY WARNING: “Exact Sciences Corporation (EXAS) Shares Bought by Jennison Associates LLC” was first published by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are viewing this report on another site, it was stolen and reposted in violation of United States and international trademark and copyright law. The legal version of this report can be viewed at https://www.thecerbatgem.com/2017/08/29/exact-sciences-corporation-exas-shares-bought-by-jennison-associates-llc.html.

EXAS has been the subject of a number of research analyst reports. Vetr cut Exact Sciences Corporation from a “hold” rating to a “sell” rating and set a $34.70 price objective for the company. in a report on Wednesday, July 12th. Benchmark Co. set a $50.00 price objective on Exact Sciences Corporation and gave the stock a “buy” rating in a report on Friday, July 7th. BidaskClub upgraded Exact Sciences Corporation from a “hold” rating to a “buy” rating in a report on Thursday, June 22nd. Goldman Sachs Group, Inc. (The) set a $33.00 price objective on Exact Sciences Corporation and gave the stock a “neutral” rating in a report on Monday, May 1st. Finally, Cowen and Company boosted their price objective on Exact Sciences Corporation from $40.00 to $45.00 and gave the stock an “outperform” rating in a report on Friday, May 5th. Six analysts have rated the stock with a hold rating, ten have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. Exact Sciences Corporation has an average rating of “Buy” and a consensus price target of $40.98.

In other news, SVP D Scott Coward sold 1,987 shares of the firm’s stock in a transaction dated Monday, July 3rd. The shares were sold at an average price of $35.21, for a total value of $69,962.27. Following the completion of the sale, the senior vice president now owns 57,603 shares in the company, valued at approximately $2,028,201.63. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Thomas D. Carey bought 2,500 shares of the stock in a transaction dated Thursday, August 17th. The stock was purchased at an average price of $37.71 per share, with a total value of $94,275.00. Following the acquisition, the director now directly owns 60,858 shares in the company, valued at approximately $2,294,955.18. The disclosure for this purchase can be found here. 4.00% of the stock is currently owned by company insiders.

Exact Sciences Corporation Company Profile

Exact Sciences Corporation is a molecular diagnostics company. The Company focuses on the early detection and prevention of some forms of cancer. It offers a non-invasive screening test called Cologuard for the early detection of colorectal cancer and pre-cancer. Its Cologuard test is a stool-based deoxyribonucleic acid (sDNA) screening test, which utilizes a multi-target approach to detect deoxyribonucleic acid (DNA) and hemoglobin biomarkers associated with colorectal cancer and pre-cancer.

Institutional Ownership by Quarter for Exact Sciences Corporation (NASDAQ:EXAS)

Receive News & Stock Ratings for Exact Sciences Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Exact Sciences Corporation and related stocks with our FREE daily email newsletter.